MMJ BioPharma challenges DEA's motion to dismiss its cannabis cultivation application for medicinal advancements.

MMJ BioPharma Cultivation, a leading cannabis researcher, is challenging the Drug Enforcement Administration's (DEA) motion to dismiss its long-pending application for cultivating pharmaceutical marijuana. The company's president, Duane Boise, emphasizes the critical importance of this approval for advancements in medicinal cannabis. The approval would come after the issuance of a DEA Analytical Lab Registration for Schedule 1 drugs to MMJ BioPharma Labs, allowing for cannabis research and development.

January 29, 2024
5 Articles